Analyst Sharon di Stefano calls two upcoming trials of Medgenics' (MDGN -3%) Infraddure Biopump for treating hepatitis C as "a leap forward for viral medicine no less important than the first studies in HIV decades ago." And with the recent failure of a Bristol-Myers treatment in clinical trials, the timing is good. Still, with a number of rival drugs being trialled, one wonders whether di Stefano is guilty of hyperbole.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Dec 4, 2014)
at MarketWatch.com (Jun 25, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs